Clinical Trials Logo

ALL, Childhood clinical trials

View clinical trials related to ALL, Childhood.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05763290 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Childhood Cancer Survivors' Affective Response to Exercise

Start date: March 22, 2023
Phase:
Study type: Observational

The primary objective of this study is to assess the feasibility of administering the Personalized Single-Category Implicit Association Test (PSC-IAT) to young adult survivors of childhood cancer. Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.

NCT ID: NCT05512169 Recruiting - Pediatric Cancer Clinical Trials

Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia

MPGx-INDALL
Start date: December 1, 2022
Phase:
Study type: Observational

A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). The project is an International multicenter setup. This collaborative research project between Switzerland and India includes one main center in Geneva that has conceptualized, designed, received grants for the study and two investigating centers in India (Puducherry and New-Delhi) involved in study design, patient care and recruitment for this specific study. All the participants for the study will be recruited form these two centers in India, and no patient recruitment is planned at main center i.e. Geneva. The study will be conducted in two phases. The first aims to investigate genetic predisposition (static germline variants) to early chemotherapy treatment related toxicities (TRTs). The second aims to investigate somatic genetic markers associated with the efficacy of steroid treatment among patients undergoing the standardized IciCLe-ALL-14 treatment protocol. A total of 500 children with ALL will be recruited to investigate primary objective of the study i.e. TRT, and a subset of 250 patients will be included to investigate another research question i.e. response to steroid therapy.

NCT ID: NCT05487651 Recruiting - B-cell Lymphoma Clinical Trials

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

ANCHOR2
Start date: October 1, 2022
Phase: Phase 1
Study type: Interventional

This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).

NCT ID: NCT04593745 Recruiting - ALL, Childhood Clinical Trials

Intraocular Pressure in Children With Acute Lymphoblastic Leukemia (ALL) Treated With High Dose Steroids

ALL
Start date: July 9, 2018
Phase: N/A
Study type: Interventional

Childhood ALL patients are treated with high dose steroids. The study will follow the intraocular pressure of children treated in according to an AIEOP-BFM protocol, during the induction phase that will be compared to the pressure before treatment. Potential risk factors for developing elevated intraocular pressure will be estimated.

NCT ID: NCT03571321 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

Start date: May 28, 2019
Phase: Phase 1
Study type: Interventional

This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).

NCT ID: NCT02879643 Recruiting - Clinical trials for Lymphoblastic Leukemia, Acute, Childhood

Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL

Start date: January 31, 2017
Phase: Phase 1
Study type: Interventional

This is a pilot study utilizing Marqibo® (vincristine sulfate liposome injection) combined with dexamethasone, mitoxantrone and asparaginase (UK ALL R3) for relapsed acute lymphoblastic leukemia (ALL).